narlaprevir: Clinical Trials

3 completed, 1 terminated. 4 Phase 2, 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	4	Completed 3, Terminated 1
Phase 3	1	Terminated 1

Follow narlaprevir: new trials by email Literature Review of narlaprevir trials Research Report on narlaprevir

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1 Narlaprevir, Ritonavir, Sofosbuvir - Chronic Hepatitis c Genotype 1	Phase 2	Completed	R-Pharm	85	2019-05-06	2022-10-31
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b Narlaprevir, Ritonavir, Daclatasvir - Chronic Hepatitis C Genotype 1b	Phase 2	Completed	R-Pharm	105	2017-11-27	2018-12-19
A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED) peginterferon alfa 2b, ribavirin, SCH 900518 - Hepatitis C, Chronic	Phase 2	Completed	Merck Sharp & Dohme LLC	111	2008-11-01	2015-01-22
Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063) Boceprevir, Narlaprevir, Peginterferon alfa-2b - Hepatitis C, Chronic, Hepacivirus	Phase 2 / Phase 3	Terminated	Merck Sharp & Dohme LLC	1954	2007-02-20	2018-09-11

Conditions studied

Hepatitis C, Chronic (2)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Hepatitis (1)  ·  Hepatitis C (1)

Sponsors

Merck Sharp & Dohme LLC (2)  ·  R-Pharm (2)

Countries

Russia (2)

Top investigators

Mikhail Samsonov (2)

Results publications

PMID 27219495